The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...
The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.
CNBC on MSN11d
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billionShares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of ...
Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...
David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback